ArticleNeurology. Clinical practice2016
Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.
Article in Neurology. Clinical practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01018537 (NARCOMS Global Multiple Sclerosis Registry), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026Review
- Assessing the association between mortality and clinical follow-up visits in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis: A Multicenter Cohort Study.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study.European journal of neurology · 2025Observational
- Etiology, effects and management of comorbidities in multiple sclerosis: recent advances.Frontiers in immunology · 2023Review
- Multiple Sclerosis and Autoimmune Comorbidities.Journal of personalized medicine · 2022Review
- Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population.Journal of health economics and outcomes research · 2022Article
- Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.Neurology · 2021Article
- Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.Journal of neurology · 2021Article
- Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.JAMA neurology · 2020Article
- Comorbidity in Multiple Sclerosis.Frontiers in neurology · 2020Review
- Wellness and the Role of Comorbidities in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Comorbidity in Multiple Sclerosis: Some Answers, More Questions.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn multiple sclerosis (MS), comorbidities have been associated with disability progression and an increased risk of mortality. We investigated the association between comorbidities and mortality in MS after accounting for disability and health behaviors.
methodsWe followed North American Research Committee on Multiple Sclerosis (NARCOMS) Registry participants who completed the Fall 2006 survey on comorbidities until death (reported or matched in the National Death Index) or date of last follow-up in 2014. We used proportional hazards regression to investigate the association between comorbidities and mortality, controlling for demographic, clinical, health behavior, and disability factors.
resultsOf 9,496 participants meeting the inclusion criteria, 502 (5.3%) were deceased. Most participants reported having ≤3 comorbid conditions (70.9% survivors, 76.9% decedents). In individual regression models, vascular, visual, and mental comorbidities were associated with increased mortality risk after adjustment for factors associated with survival. When combined into a single model, vascular (hazard ratio 1.269; 1.041-1.547), visual (1.490; 1.199-1.852), and mental comorbidities (excluding anxiety, 1.239; 1.024-1.499) remained independently associated with an increased risk of mortality.
conclusionsPresence of comorbidities was independently associated with an increased risk of mortality as compared to absence of comorbidities after adjusting for factors associated with survival. Specifically, vascular, visual, and mental comorbidities increased the risk of mortality. This highlights the need for clinicians to attend to these comorbidities, which can be modified by treatments or other interventions, and potentially reduce the risk of mortality in persons with MS who have these conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.